Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Elevated platelets, advanced BCLC stage tied to poor survival in sorafenib-treated HCC patients

02 Jul 2019

Hepatocellular carcinoma (HCC) patients receiving sorafenib may have poor survival if they present with pretreatment elevated platelets or have advanced Barcelona Clinic Liver Cancer (BCLC) stage, a recent study has shown.

In total, 1,336 patients (median age, 65 years; interquartile range [IQR], 55–71; 70 percent male) were evaluated, of whom 127 received sorafenib and were included in the study. Median overall survival (OS) in all patients was 8 months (IQR, 2–17).

Multivariate analysis revealed that survival was associated with platelets >/<250,000 mm3 (2 vs 8 months; p=0.01) and BCLC stage (A/B, 13 vs C/D, 6 months; p=0.04). Subanalysis of patients also showed the independent association of BCLC stage C and platelets >/<250,000 mm3 with survival (2 vs 5.5 months; p=0.03)

Survival was longer if patients experienced any side effects from sorafenib use (11 vs 2 months; p=0.009). However, patients who stopped sorafenib treatment because of side effects had shorter survival than those who were able to tolerate them and continue treatment (7.5 vs 13 months; p=0.01).

This retrospective analysis sought to examine the efficacy, safety profile and variables associated with survival in HCC patients treated with sorafenib in South America. Between January 2010 and June 2017, the authors examined HCC patients who received sorafenib from eight medical centres in five South American countries.

OS, which was defined as time from sorafenib initiation to death or last follow-up, was the primary endpoint of the study. Cox proportional hazard regression and log-rank tests were used to assess the risk factors for decreased OS.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).